Increased Cerebrospinal Fluid F2-Isoprostanes are Associated with Aging and Latent Alzheimer’s Disease as Identified by Biomarkers

被引:0
|
作者
Thomas J. Montine
Elaine R. Peskind
Joseph F. Quinn
Angela M. Wilson
Kathleen S. Montine
Douglas Galasko
机构
[1] University of Washington,Department of Pathology
[2] University of Washington,Department of Psychiatry and Behavioral Sciences
[3] VA Puget Sound Health Care System,Mental Illness Research, Education, and Clinical Center
[4] Oregon Health and Science University and Portland VA Medical Center,Department of Neurology
[5] University of California at San Diego,Department of Neurosciences
来源
NeuroMolecular Medicine | 2011年 / 13卷
关键词
Alzheimer’s disease; Cerebrospinal fluid; Biomarkers; Aβ; Tau; F; -isoprostanes;
D O I
暂无
中图分类号
学科分类号
摘要
Alzheimer’s disease (AD) is a common age-related chronic illness with latent, prodrome, and fully symptomatic dementia stages. Increased free radical injury to regions of brain is one feature of prodrome and dementia stages of AD; however, it also is associated with advancing age. This raises the possibility that age-related free radical injury to brain might be caused in part or in full by latent AD. We quantified free radical injury in the central nervous system with cerebrospinal fluid (CSF) F2-isoprostanes (IsoPs) in 421 clinically normal individuals and observed a significant increase over the adult human lifespan (P < 0.001). Using CSF amyloid (A) β42 and tau, we defined normality using results from 28 clinically normal individuals <50 years old, and then stratified 74 clinically normal subjects ≥60 years into those with CSF that had normal CSF Aβ42 and tau (n = 37); abnormal CSF Aβ42 and tau, the biomarker signature of AD (n = 24); decreased Aβ42 only (n = 4); or increased tau only (n = 9). Increased CSF F2-IsoPs were present in clinically normal subjects with the biomarker signature of AD (P < 0.05) and those subjects with increased CSF tau (P < 0.001). Finally, we analyzed the relationship between age and CSF F2-IsoPs for those clinically normal adults with normal CSF (n = 37) and those with abnormal CSF Aβ42 and/or tau (n = 37); only those with normal CSF demonstrated a significant increase with age (P < 0.01). These results show that CSF F2-IsoPs increased across the human lifespan and that this age-related increase in free radical injury to brain persisted after culling those with laboratory evidence of latent AD.
引用
收藏
页码:37 / 43
页数:6
相关论文
共 50 条
  • [41] Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease
    Heslegrave, Amanda
    Heywood, Wendy
    Paterson, Ross
    Magdalinou, Nadia
    Svensson, Johan
    Johansson, Per
    Ohrfelt, Annika
    Blennow, Kaj
    Hardy, John
    Schott, Jonathan
    Mills, Kevin
    Zetterberg, Henrik
    MOLECULAR NEURODEGENERATION, 2016, 11
  • [42] Serotonin Receptor Gene Polymorphisms Are Associated with Cerebrospinal Fluid, Genetic, and Neuropsychological Biomarkers of Alzheimer's Disease
    Leko, Mirjana Babic
    Perkovic, Matea Nikolac
    Spanic, Ena
    Strac, Dubravka Svob
    Pleic, Nikolina
    Vogrinc, Zeljka
    Gunjaca, Ivana
    Bezovan, Dora
    Erjavec, Gordana Nedic
    Klepac, Natasa
    Borovecki, Fran
    Zemunik, Tatijana
    Pivac, Nela
    Hof, Patrick R.
    Simic, Goran
    BIOMEDICINES, 2022, 10 (12)
  • [43] Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease
    Fagan, Anne M.
    Perrin, Richard J.
    BIOMARKERS IN MEDICINE, 2012, 6 (04) : 455 - 476
  • [44] Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: The Present and the Future
    Ghidoni, Roberta
    Benussi, Luisa
    Paterlini, Anna
    Albertini, Valentina
    Binetti, Giuliano
    Emanuele, Enzo
    NEURODEGENERATIVE DISEASES, 2011, 8 (06) : 413 - 420
  • [45] Cerebrospinal fluid microRNAs as potential biomarkers in Alzheimer's disease
    Eddin, Ahmed Noor
    Hamsho, Khaled
    Adi, Ghaith
    Al-Rimawi, Mohammed
    Alfuwais, Mohammed
    Rab, Saleha Abdul
    Alkattan, Khaled
    Yaqinuddin, Ahmed
    FRONTIERS IN AGING NEUROSCIENCE, 2023, 15
  • [46] Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
    Huynh, Rose Ann
    Mohan, Chandra
    FRONTIERS IN NEUROLOGY, 2017, 8
  • [47] Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid
    Riekse, Robert G.
    Li, Ge
    Petrie, Eric C.
    Leverenz, James B.
    Vavrek, Darcy
    Vuletic, Simona
    Albers, John J.
    Montine, Thomas J.
    Lee, Virginia M. -Y.
    Lee, Michael
    Seubert, Peter
    Galasko, Douglas
    Schellenberg, Gerard D.
    Hazzard, William R.
    Peskind, Elaine R.
    JOURNAL OF ALZHEIMERS DISEASE, 2006, 10 (04) : 399 - 406
  • [48] MicroRNAs in Human Cerebrospinal Fluid as Biomarkers for Alzheimer's Disease
    Lusardi, Theresa A.
    Phillips, Jay I.
    Wiedrick, Jack T.
    Harrington, Christina A.
    Lind, Babett
    Lapidus, Jodi A.
    Quinn, Joseph F.
    Saugstad, Julie A.
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 55 (03) : 1223 - 1233
  • [49] Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in the Era of Disease-Modifying Treatments
    Paraskevas, George P.
    Kapaki, Elisabeth
    BRAIN SCIENCES, 2021, 11 (10)
  • [50] Cerebral Amyloid Angiopathy-Related Microbleeds and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease
    Noguchi-Shinohara, Moeko
    Komatsu, Junji
    Samuraki, Miharu
    Matsunari, Ichiro
    Ikeda, Tokuhei
    Sakai, Kenji
    Hamaguchi, Tsuyoshi
    Ono, Kenjiro
    Nakamura, Hiroyuki
    Yamada, Masahito
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 55 (03) : 905 - 913